EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
According to international consensus, metformin is acknowledged as a first-line therapeutic agent for type 2 diabetes mellitus (T2DM). However, in most cases this treatment eventually requires intensification by supplementation with other hypoglycemic medications. The aim of the EDGE study (Effectiv...
Saved in:
| Main Author: | Gagik Radikovich Galstyan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2013-06-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/3761 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01) -
Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01) -
Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01) -
First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
by: Karina Oganesovna Galstyan, et al.
Published: (2016-01-01) -
Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)